We are studying how safe and effective MB-CART2019.1 is for children and teens with relapsed or refractory B-cell cancers. This research aims to find better treatment options for those who haven't responded to other therapies.
Health conditions and diseases that the clinical trial is designed to study and treat.
Refractory or recurrent B-cell lymphoma refers to a type of cancer where B-cells, a kind of white blood cell, do not respond to treatment or return after treatment. This condition often requires alternative therapies due to its resistance to standard treatments.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
